BioWorld

April 1, 2003

View Archived Issues

Regeneron Plummets On Early Phase III Results With Axokine

Preliminary results from Regeneron Pharmaceutical Inc.'s Phase III trial with the obesity drug Axokine are being called mixed, but the market's reaction was unambiguous, taking away 56.6 percent of the stock's value. Read More

Palatin Raises $19M Privately For LeuTech, PT 141 Programs

Read More

Industry, Academia Collaborate To Crack Stubborn Enigma Of HCV's Unswerving Hepatic-Cell Tropism

Read More

UK Office Fines Genzyme Over Practices Related To Cerezyme

Read More

Other News To Note

Read More